CYTK vs PATH
Cytokinetics Inc (CYTK) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Cytokinetics Inc (CYTK) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CYTK revenue for 2024-12-31 was $18.5M. Net income was -$589.5M. Revenue was up 145.3% from 2023-12-31 to 2024-12-31. CYTK currently screens at market cap $4.05B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CYTK currently screens at market cap $4.05B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CYTK and PATH stock pages for the full models.
Not investment advice.